Drug Discovery Featured Articles & Applications

  1. Should We Explore Suicidality In Animals During Preclinical Drug Development? 11/19/2024

    An adverse side effect for some drugs is suicidal ideation and behavior (SIB). Investigating SIB in animal studies represents the closest approximation to human SIB, yet the FDA Modernization Act 3.0 obligates us to reduce unnecessary animal testing. Let's examine this with data-driven research.

  2. How To Overcome Immune Rejection In iPSC-based Gene Therapy 11/6/2024

    Even when induced pluripotent stem cells (iPSCs) are derived from the patient's cells, immune rejection can still occur. This article explores the causes as well as strategies to overcome immune rejection.

  3. Emerging Partnership Trends In Oligo-Based Medicines 11/6/2024

    The oligonucleotides sector is quickly evolving and seeing more industry partnerships than ever before. We caught up with DeciBio's Carl Schoellhammer and Phillip Leclair for their analysis.

  4. Exploring Sanofi R&D's Batch Monitoring Initiative 10/23/2024

    The project established predictability during testing and release for the production of medicine to support clinical trials.

  5. Panavance Details IND Prep Ahead Of FDA Submission For Ovarian Cancer Trial 10/23/2024

    Panavance CEO Greg Bosch discusses the company’s pursuit of a second trial for misetionamide, walking us through IND preparations, CRO selection, and securing funding. 

  6. iPSC-based Gene Therapy: Applications And Challenges 10/15/2024

    Induced pluripotent stem cells (iPSCs) are generated by reprogramming adult somatic cells into a pluripotent state, meaning they can develop into any cell type in the human body. This has tremendous potential in regenerative medicine and gene therapy.

  7. Restoring Immune Homeostasis As A Development Approach To Treat And Modify Inflammatory Disease 10/8/2024

    Drawing from experiences with ongoing work at AnaptysBio, Inc., senior VP of research Martin Dahl, Ph.D., shares three considerations when developing immune cell modulators to treat and modify inflammatory disease.

  8. Keys To Successful CMC Source Document Preparation For Cell & Gene Therapies 10/1/2024

    Chemistry, manufacturing, and controls (CMC) source documents are the foundation for module 3 of a cell/gene therapy FDA regulatory submission.

  9. Tracking The Latest Developments In CAR T Safety And Efficacy 9/27/2024

    Here are some updates on the industry's quest to enhance CAR T cells' ability to target and destroy cancer while reducing adverse effects.

  10. Araris Doubles Down With Dual-payload ADC 9/24/2024

    Antibody-drug conjugates usually deliver one payload type, which can overlook cancer’s complexity. A single ADC delivering two separate payloads could be the answer.